By Tom Salemi
Barrx Medical Inc. has done an effective job of navigating its HALO radiofrequency ablation device onto the commercial markets...
Barrx Medical: Making A Case For Ablation
Listen to this article
Barrx Medical set out seven years ago to compile enough clinical trial data to prove not only that ablation is a safe and effective way of treating Barrett's esophagus, but also that is cheaper than endoscopic surveillance. Its patience is beginning to pay off.
Candid conversations with C-suite leaders.
More from Global Vision
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
• By
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
• By
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.